Business Wire

Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies

BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...

Hyperfine Announces Enrollment of First Patient in Study to Expand Intended Use of the Swoop(R) System with Contrast Agents

(Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain--the Swoop (R) system--today ...
Morningstar

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

Bayer revealed first results of the pediatric study from the pivotal clinical development program QUANTI for its low-dose MRI contrast agent QUANTI Pediatric evaluated the pharmacokinetics and safety ...
Business Wire

GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...
Nasdaq

Altimmune Reports Data From Phase 2, MRI-based Body Composition Sub-study Of Pemvidutide

(RTTNews) - Altimmune (ALT) presented data from Phase 2, MRI-based body composition sub-study of pemvidutide in subjects with overweight and obesity. In the sub-study of 67 subjects from the Phase 2 ...